相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF) agents after previous failure of an anti-TNF agent?
A. Finckh et al.
ANNALS OF THE RHEUMATIC DISEASES (2010)
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs
Josef S. Smolen et al.
ANNALS OF THE RHEUMATIC DISEASES (2010)
Direct Comparison of Treatment Responses, Remission Rates, and Drug Adherence in Patients With Rheumatoid Arthritis Treated With Adalimumab, Etanercept, or Infliximab Results From Eight Years of Surveillance of Clinical Practice in the Nationwide Danish DANBIO Registry
Merete Lund Hetland et al.
ARTHRITIS AND RHEUMATISM (2010)
Switching TNF-alpha antagonists in rheumatoid arthritis: The experience of the LORHEN registry
Roberto Caporali et al.
AUTOIMMUNITY REVIEWS (2010)
The effectiveness of anti-TNF-α therapies when used sequentially in rheumatoid arthritis patients: a systematic review and meta-analysis
Suzanne Lloyd et al.
RHEUMATOLOGY (2010)
Frequency and Effectiveness of Dose Increase of Adalimumab, Etanercept, and Infliximab in Daily Clinical Practice
M. Blom et al.
ARTHRITIS CARE & RESEARCH (2010)
TNF-alpha Antagonist Survival Rate in a Cohort of Rheumatoid Arthritis Patients Observed under Conditions of Standard Clinical Practice
Antonio Marchesoni et al.
CONTEMPORARY CHALLENGES IN AUTOIMMUNITY (2009)
Pattern and Predictors of the Initiation of Biologic Agents for the Treatment of Rheumatoid Arthritis in the United States: An Analysis Using a Large Observational Data Bank
Esi Morgan DeWitt et al.
CLINICAL THERAPEUTICS (2009)
Categorization of infliximab dose changes and healthcare utilization and expenditures for patients with rheumatoid arthritis in commercially insured and Medicare-eligible populations
Kavita V. Nair et al.
CURRENT MEDICAL RESEARCH AND OPINION (2009)
Therapeutic agents for patients with rheumatoid arthritis and an inadequate response to tumour necrosis factor-α antagonists
John D. Isaacs
EXPERT OPINION ON BIOLOGICAL THERAPY (2009)
The Reason for Discontinuation of the First Tumor Necrosis Factor (TNF) Blocking Agent Does Not Influence the Effect of a Second TNF Blocking Agent in Patients with Rheumatoid Arthritis
Marlies Blom et al.
JOURNAL OF RHEUMATOLOGY (2009)
British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of rheumatoid arthritis (after the first 2 years)
Raashid Luqmani et al.
RHEUMATOLOGY (2009)
IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial
P. Emery et al.
ANNALS OF THE RHEUMATIC DISEASES (2008)
Treatment persistence with adalimumab, etanercept, or infliximab in combination with methotrexate and the effects on health care costs in patients with rheumatoid arthritis
Boxiong Tang et al.
CLINICAL THERAPEUTICS (2008)
Changing patterns of medication use in patients with rheumatoid arthritis in a Medicaid population
C. G. Grijalva et al.
RHEUMATOLOGY (2008)
Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy
M. C. Genovese et al.
ANNALS OF THE RHEUMATIC DISEASES (2008)
Treatment response to a second or third TNF-inhibitor in RA:: results from the South Swedish Arthritis Treatment Group Register
J. A. Karisson et al.
RHEUMATOLOGY (2008)
B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents
Axel Finckh et al.
ARTHRITIS AND RHEUMATISM (2007)
Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis - Results from a large UK national cohort study
Kimme L. Hyrich et al.
ARTHRITIS AND RHEUMATISM (2007)
Clinical practice format for choosing a second-line disease modifying anti-rheumatic drug in early rheumatoid arthritis after failure of 6 months' first-line DMARD therapy
Olivier Meyer et al.
JOINT BONE SPINE (2007)
British society for rheumatology and british health professionals in rheumatology guideline for the management of rheumatoid arthritis (the first two years)
R. Luqmani et al.
RHEUMATOLOGY (2006)
Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy - Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks
Stanley B. Cohen et al.
ARTHRITIS AND RHEUMATISM (2006)
Evidence for differential acquired drug resistance to anti-tumour necrosis factor agents in rheumatoid arthritis
A. Finckh et al.
ANNALS OF THE RHEUMATIC DISEASES (2006)
Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period
JJ Gomez-Reino et al.
ARTHRITIS RESEARCH & THERAPY (2006)
Real-world utilization of DMARDs and biologics in rheumatoid arthritis: the RADIUS (rheumatoid arthritis disease-modifying anti-rheumatic drug intervention and utilization study) study
A Gibofsky et al.
CURRENT MEDICAL RESEARCH AND OPINION (2006)
Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data
HD Quan et al.
MEDICAL CARE (2005)
Abatacept for rheumatoid arthritis refractory to tumor necrosis factor α inhibition
MC Genovese et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Patterns of use, dosing, and economic impact of biologic agent use in patients with rheumatoid arthritis: a retrospective cohort study
TD Gilbert et al.
BMC MUSCULOSKELETAL DISORDERS (2004)
分享论文
